Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Huifeng Niu

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
Hematological Oncology|December 7, 2002
The proto-oncogene BCL-6 in normal and malignant B cell developmentHuifeng Niu
Frontiers in Oncology|September 18, 2015
Scientific Rationale Supporting the Clinical Development Strategy for the Investigational Aurora A Kinase Inhibitor Alisertib in CancerHuifeng Niu, Mark Manfredi, Jeffrey A Ecsedy
The Journal of Experimental Medicine|July 16, 2003
BCL6 controls the expression of the B7-1/CD80 costimulatory receptor in germinal center B cellsHuifeng Niu, Giorgio Cattoretti, Riccardo Dalla-Favera
Nature Immunology|September 6, 2005
BCL6 interacts with the transcription factor Miz-1 to suppress the cyclin-dependent kinase inhibitor p21 and cell cycle arrest in germinal center B cellsRyan T Phan, Masumichi Saito, Katia Basso, et al.
Plos One|August 11, 2012
BRAFV600E negatively regulates the AKT pathway in melanoma cell linesBrenden Chen, Christine Tardell, Brian Higgins, et al.
Clinical Lung Cancer|November 14, 2022
Real-world ALK Testing Trends in Patients With Advanced Non-Small-Cell Lung Cancer in the United StatesHuamao M Lin, Yanyu Wu, Yu Yin, et al.
Blood|August 28, 2004
Tracking CD40 signaling during germinal center developmentKatia Basso, Ulf Klein, Huifeng Niu, et al.
Leukemia & Lymphoma|June 19, 2004
Molecular pathogenesis of non-Hodgkin's lymphoma: the role of Bcl-6Laura Pasqualucci, Oxana Bereshchenko, Oxana Bereschenko, et al.
Journal of Clinical Pharmacology|April 14, 2010
The safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of RO5068760, an MEK inhibitor, in healthy volunteers: assessment of target suppressionLucy Lee, Huifeng Niu, Petra Goelzer, et al.
Cancer Research|June 28, 2011
Identification of the MEK1(F129L) activating mutation as a potential mechanism of acquired resistance to MEK inhibition in human cancers carrying the B-RafV600E mutationHuisheng Wang, Sherif Daouti, Wen-Hui Li, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Hematological Oncology|December 7, 2002
The proto-oncogene BCL-6 in normal and malignant B cell developmentHuifeng Niu
Frontiers in Oncology|September 18, 2015
Scientific Rationale Supporting the Clinical Development Strategy for the Investigational Aurora A Kinase Inhibitor Alisertib in CancerHuifeng Niu, Mark Manfredi, Jeffrey A Ecsedy
The Journal of Experimental Medicine|July 16, 2003
BCL6 controls the expression of the B7-1/CD80 costimulatory receptor in germinal center B cellsHuifeng Niu, Giorgio Cattoretti, Riccardo Dalla-Favera
Nature Immunology|September 6, 2005
BCL6 interacts with the transcription factor Miz-1 to suppress the cyclin-dependent kinase inhibitor p21 and cell cycle arrest in germinal center B cellsRyan T Phan, Masumichi Saito, Katia Basso, et al.
Plos One|August 11, 2012
BRAFV600E negatively regulates the AKT pathway in melanoma cell linesBrenden Chen, Christine Tardell, Brian Higgins, et al.
Clinical Lung Cancer|November 14, 2022
Real-world ALK Testing Trends in Patients With Advanced Non-Small-Cell Lung Cancer in the United StatesHuamao M Lin, Yanyu Wu, Yu Yin, et al.
Blood|August 28, 2004
Tracking CD40 signaling during germinal center developmentKatia Basso, Ulf Klein, Huifeng Niu, et al.
Leukemia & Lymphoma|June 19, 2004
Molecular pathogenesis of non-Hodgkin's lymphoma: the role of Bcl-6Laura Pasqualucci, Oxana Bereshchenko, Oxana Bereschenko, et al.
Journal of Clinical Pharmacology|April 14, 2010
The safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of RO5068760, an MEK inhibitor, in healthy volunteers: assessment of target suppressionLucy Lee, Huifeng Niu, Petra Goelzer, et al.
Cancer Research|June 28, 2011
Identification of the MEK1(F129L) activating mutation as a potential mechanism of acquired resistance to MEK inhibition in human cancers carrying the B-RafV600E mutationHuisheng Wang, Sherif Daouti, Wen-Hui Li, et al.
Pageof 3